Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia.
COVID-19
cancer
diabetes
multiple sclerosis
vaccine hesitancy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
26 May 2022
26 May 2022
Historique:
received:
10
05
2022
revised:
23
05
2022
accepted:
23
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
As COVID-19 vaccinations became available and were proven effective in preventing serious infection, uptake amongst individuals varied, including in medically vulnerable populations. This cross-sectional multi-site study examined vaccine uptake, hesitancy, and explanatory factors amongst people with serious and/or chronic health conditions, including the impact of underlying disease on attitudes to vaccination. A 42-item survey was distributed to people with cancer, diabetes, or multiple sclerosis across ten Australian health services from 30 June to 5 October 2021. The survey evaluated sociodemographic and disease-related characteristics and incorporated three validated scales measuring vaccine hesitancy and vaccine-related beliefs generally and specific to their disease: the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale and the Disease Influenced Vaccine Acceptance Scale-Six. Among 4683 participants (2548 [54.4%] female, 2108 [45.0%] male, 27 [0.6%] other; mean [SD] age, 60.6 [13.3] years; 3560 [76.0%] cancer, 842 [18.0%] diabetes, and 281 [6.0%] multiple sclerosis), 3813 (81.5%) self-reported having at least one COVID-19 vaccine. Unvaccinated status was associated with younger age, female sex, lower education and income, English as a second language, and residence in regional areas. Unvaccinated participants were more likely to report greater vaccine hesitancy and more negative perceptions toward vaccines. Disease-related vaccine concerns were associated with unvaccinated status and hesitancy, including greater complacency about COVID-19 infection, and concerns relating to vaccine efficacy and impact on their disease and/or treatment. This highlights the need to develop targeted strategies and education about COVID-19 vaccination to support medically vulnerable populations and health professionals.
Identifiants
pubmed: 35746458
pii: vaccines10060851
doi: 10.3390/vaccines10060851
pmc: PMC9230066
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Health Expect. 2000 Mar;3(1):6-16
pubmed: 11281907
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Vaccines (Basel). 2021 Jul 16;9(7):
pubmed: 34358208
Expert Rev Vaccines. 2022 Apr;21(4):435-451
pubmed: 35112973
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
J Cancer Res Clin Oncol. 2022 Jun;148(6):1363-1374
pubmed: 35218401
Behav Med. 2022 Jun 15;:1-10
pubmed: 35703037
Psychol Med. 2020 Dec 11;:1-15
pubmed: 33305716
Mult Scler Relat Disord. 2021 Oct;55:103175
pubmed: 34343866
J Behav Med. 2022 Jan 15;:
pubmed: 35032254
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
JMIR Public Health Surveill. 2022 Jan 5;8(1):e29872
pubmed: 34709184
Front Psychol. 2020 Oct 19;11:575950
pubmed: 33192883
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Asia Pac J Clin Oncol. 2022 Jan 18;:
pubmed: 35043559
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Hum Vaccin Immunother. 2021 Nov 02;17(11):4048-4056
pubmed: 34357827
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
Healthcare (Basel). 2021 Mar 19;9(3):
pubmed: 33808758
Eur J Cancer. 2021 Aug;153:260-264
pubmed: 34183225